- ►oxfordjournals.org M Aapro, PA Abrahamsson, JJ Body, RE Coleman … - Annals of Oncology, 2007 - Eur Soc Med Oncology Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal
complications in patients, and have substantially decreased the prevalence of
such events since their introduction. Today, a broad range of BP with ... Cited by 72 - Related articles - BL Direct - All 6 versions
RS Israeli, CW Ryan, LL Jung - The Journal of Urology, 2007 - Elsevier Bone mineral density loss and related fractures were recently established as
significant adverse events associated with androgen deprivation therapy.
Patients with nonmetastatic prostate cancer receiving androgen deprivation ... Cited by 15 - Related articles - All 16 versions
CS Higano - nature clinical practice UROLOGY, 2008 - medscape.com Androgen deprivation therapy (ADT) alone or in combination with radiation
therapy or other drugs is increasingly used for the treatment of localized,
high-risk, or biochemical relapse of prostate cancer (PC). Bone mineral ... Cited by 14 - Related articles - BL Direct - All 6 versions
- ►ascopubs.org F Saad, JD Adachi, JP Brown, LA Canning, KA … - Journal of Clinical Oncology, 2008 - jco.ascopubs.org Methods Studies evaluating the incidence and prevalence of CTIBL in early breast
and prostate cancer patients and trials evaluating the preventative role of
bisphosphonates were identified by a search of the PubMed and Cochrane ... Cited by 11 - Related articles - All 5 versions
H Isbarn, L Boccon-Gibod, PR Carroll, F … - European Urology, 2009 - Elsevier Androgen deprivation therapy (ADT) is increasingly used for the treatment of
prostate cancer (PCa), even in clinical settings in which there is no
evidence-based proof of prolonged overall survival (OS). ADT, however, may ... Cited by 11 - Related articles - All 19 versions
- ►endojournals.org SL Greenspan - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Prostate cancer is the most common visceral malignancy in men. Androgen
deprivation therapy (ADT) is commonly used in patients with nonmetastatic
prostate cancer and is associated with significant bone loss and fractures. ... Cited by 9 - Related articles - BL Direct - All 5 versions
- ►alphamedpress.org AM Brufsky - The oncologist, 2008 - AlphaMed Press Disclosure: AMB has participated in the speakers bureau for Novartis
Pharmaceuticals. Funding for medical editorial assistance was provided by
Novartis Pharmaceuticals Corporation. No other potential conflicts of ... Cited by 9 - Related articles - BL Direct - All 10 versions
- ►ascopubs.org SL Greenspan, JB Nelson, DL Trump, JM … - Journal of Clinical Oncology, 2008 - jco.ascopubs.org Results Men initially randomly assigned to alendronate and randomly reassigned
at year 2 to continue had additional bone density gains at the spine (mean, 2.3%
± 0.7) and hip (mean, 1.3% ± 0.5%; both P < .01); those randomly assigned ... Cited by 8 - Related articles - All 5 versions
- ►nih.gov EFT Yee, RE White, GH Murata, C Handanos … - Journal of General Internal Medicine, 2007 - Springer Page 1. Osteoporosis Management in Prostate Cancer Patients Treated with Androgen
Deprivation Therapy Ellen FT Yee, MD, MPH 1,3 , Robert ... Cited by 7 - Related articles - BL Direct - All 4 versions
RA Adler - Current Opinion in Endocrinology, Diabetes and …, 2007 - journals.lww.com Purpose of review: Patients treated for cancer may be at risk for osteoporosis
and fracture. Evaluation and treatment of patients with cancer treatment-induced
bone loss should lead to fewer fractures. This review will help clinicians ... Cited by 6 - Related articles - BL Direct - All 3 versions
